Login Register Cart 0
Generic placeholder image

Pharmaceutical Nanotechnology

Editor-in-Chief

ISSN (Print): 2211-7385
ISSN (Online): 2211-7393

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Carbon-based Nanomaterials for Delivery of Small RNA Molecules: A Focus on Potential Cancer Treatment Applications

Author(s): Saffiya Habib and Moganavelli Singh*

Volume 10, Issue 3, 2022

Published on: 26 August, 2022

Page: [164 - 181] Pages: 18

DOI: 10.2174/2211738510666220606102906

Price: $65

conference banner
Abstract

Background: Nucleic acid-mediated therapy holds immense potential in treating recalcitrant human diseases such as cancer. This is underscored by advances in understanding the mechanisms of gene regulation. In particular, the endogenous protective mechanism of gene silencing known as RNA interference (RNAi) has been extensively exploited.

Methods: We review the developments from 2011 to 2021 using nano-graphene oxide, carbon nanotubes, fullerenes, carbon nanohorns, carbon nanodots and nanodiamonds for the delivery of therapeutic small RNA molecules.

Results: Appropriately designed effector molecules such as small interfering RNA (siRNA) can, in theory, silence the expression of any disease-causing gene. Alternatively, siRNA can be generated in vivo by introducing plasmid-based short hairpin RNA (shRNA) expression vectors. Other small RNAs, such as micro RNA (miRNA), also function in post-transcriptional gene regulation and are aberrantly expressed under disease conditions. The miRNA-based therapy involves either restoration of miRNA function through the introduction of miRNA mimics; or the inhibition of miRNA function by delivering anti-miRNA oligomers. However, the large size, hydrophilicity, negative charge and nuclease-sensitivity of nucleic acids necessitate an appropriate carrier for their introduction as medicine into cells.

Conclusion: While numerous organic and inorganic materials have been investigated for this purpose, the perfect carrier agent remains elusive. Carbon-based nanomaterials have received widespread attention in biotechnology recently due to their tunable surface characteristics and mechanical, electrical, optical and chemical properties.

Keywords: Cancer, carbon-based nanoparticles, small RNA, therapeutics, delivery, nucleic acids.

« Previous Next »
Graphical Abstract

[1]
Lammers T, Ferrari M. The success of nanomedicine. Nano Today 2020; 31100853.
[http://dx.doi.org/10.1016/j.nantod.2020.100853] [PMID: 34707725]
[2]
Jagaran K, Singh M. Nanomedicine for neurodegenerative disorders: Focus on Alzheimer’s and Parkinson’s diseases. Int J Mol Sci 2021; 22(16): 9082.
[http://dx.doi.org/10.3390/ijms22169082] [PMID: 34445784]
[3]
Tran P, Lee SE, Kim DH, Pyo YC, Park JS. Recent advances of nanotechnology for the delivery of anticancer drugs for breast cancer treatment. J Pharm Investig 2020; 50(3): 261-70.
[http://dx.doi.org/10.1007/s40005-019-00459-7]
[4]
Cancela-Vila N. Nanotechnology applied to the transport of antibiotics in orthopedics and traumatology Acta Ortop Mex 2020; 34(4): 249-53.
[http://dx.doi.org/10.35366/97560] [PMID: 33535284]
[5]
Yu M, Wu J, Shi J, Farokhzad OC. Nanotechnology for protein delivery: Overview and perspectives. J Control Release 2016; 240: 24-37.
[http://dx.doi.org/10.1016/j.jconrel.2015.10.012] [PMID: 26458789]
[6]
Petkar KC, Patil SM, Chavhan SS, et al. An overview of nanocarrier-based adjuvants for vaccine delivery. Pharmaceutics 2021; 13(4): 455.
[http://dx.doi.org/10.3390/pharmaceutics13040455] [PMID: 33801614]
[7]
Jin JO, Kim G, Hwang J, Han KH, Kwak M, Lee PCW. Nucleic acid nanotechnology for cancer treatment. Biochim Biophys Acta Rev Cancer 2020; 1874(1): 188377.
[http://dx.doi.org/10.1016/j.bbcan.2020.188377] [PMID: 32418899]
[8]
Das M, Musetti S, Huang L. RNA interference-based cancer drugs: The roadblocks, and the “delivery” of the promise. Nucleic Acid Ther 2019; 29(2): 61-6.
[http://dx.doi.org/10.1089/nat.2018.0762] [PMID: 30562145]
[9]
Napoli C, Lemieux C, Jorgensen R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 1990; 2(4): 279-89.
[http://dx.doi.org/10.2307/3869076] [PMID: 12354959]
[10]
Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391(6669): 806-11.
[http://dx.doi.org/10.1038/35888] [PMID: 9486653]
[11]
Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411(6836): 494-8.
[http://dx.doi.org/10.1038/35078107] [PMID: 11373684]
[12]
Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001; 15(2): 188-200.
[http://dx.doi.org/10.1101/gad.862301] [PMID: 11157775]
[13]
Padayachee J, Daniels A, Balgobind A, Ariatti M, Singh M. HER-2/neu and MYC gene silencing in breast cancer: Therapeutic potential and advancement in nonviral nanocarrier systems. Nanomedicine 2020; 15(14): 1437-52.
[http://dx.doi.org/10.2217/nnm-2019-0459] [PMID: 32515263]
[14]
Daniels AN, Singh M. Sterically stabilized siRNA:gold nanocomplexes enhance c-MYC silencing in a breast cancer cell model. Nanomedicine 2019; 14(11): 1387-401.
[http://dx.doi.org/10.2217/nnm-2018-0462] [PMID: 31166141]
[15]
Moore CB, Guthrie EH, Huang MT-H, Taxman DJ. Short hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown. Methods Mol Biol 2010; 629: 141-58.
[PMID: 20387148]
[16]
Hammond SM. An overview of microRNAs. Adv Drug Deliv Rev 2015; 87: 3-14.
[http://dx.doi.org/10.1016/j.addr.2015.05.001] [PMID: 25979468]
[17]
Rupaimoole R, Slack FJ. MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 2017; 16(3): 203-22.
[http://dx.doi.org/10.1038/nrd.2016.246] [PMID: 28209991]
[18]
Fu Y, Chen J, Huang Z. Recent progress in microRNA-based delivery systems for the treatment of human disease. ExRNA 2019; 1(1): 24.
[http://dx.doi.org/10.1186/s41544-019-0024-y]
[19]
Paul S, Bravo Vázquez LA, Pérez Uribe S, Roxana Reyes-Pérez P, Sharma A. Current status of microRNA-based therapeutic approaches in neurodegenerative disorders. Cells 2020; 9(7): 1698.
[http://dx.doi.org/10.3390/cells9071698] [PMID: 32679881]
[20]
Singh M, Hawtrey A, Ariatti M. Lipoplexes with biotinylated transferrin accessories: Novel, targeted, serum-tolerant gene carriers. Int J Pharm 2006; 321(1-2): 124-37.
[http://dx.doi.org/10.1016/j.ijpharm.2006.05.005] [PMID: 16806757]
[21]
Chandrasekaran AR. Nuclease resistance of DNA nanostructures. Nat Rev Chem 2021; 5(4): 225-39.
[http://dx.doi.org/10.1038/s41570-021-00251-y] [PMID: 33585701]
[22]
van de Water FM, Boerman OC, Wouterse AC, Peters JG, Russel FG, Masereeuw R. Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos 2006; 34(8): 1393-7.
[http://dx.doi.org/10.1124/dmd.106.009555] [PMID: 16714375]
[23]
Xu CF, Wang J. Delivery systems for siRNA drug development in cancer therapy. Asian J Pharm Sci 2015; 10(1): 1-12.
[http://dx.doi.org/10.1016/j.ajps.2014.08.011]
[24]
Braasch DA, Jensen S, Liu Y, et al. RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 2003; 42(26): 7967-75.
[http://dx.doi.org/10.1021/bi0343774] [PMID: 12834349]
[25]
Czauderna F, Fechtner M, Dames S, et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 2003; 31(11): 2705-16.
[http://dx.doi.org/10.1093/nar/gkg393] [PMID: 12771196]
[26]
Sharma VK, Watts JK. Oligonucleotide therapeutics: Chemistry, delivery and clinical progress. Future Med Chem 2015; 7(16): 2221-42.
[http://dx.doi.org/10.4155/fmc.15.144] [PMID: 26510815]
[27]
Bernardo BC, Ooi JY, Lin RC, McMullen JR. miRNA therapeutics: A new class of drugs with potential therapeutic applications in the heart. Future Med Chem 2015; 7(13): 1771-92.
[http://dx.doi.org/10.4155/fmc.15.107] [PMID: 26399457]
[28]
Crombez L, Aldrian-Herrada G, Konate K, et al. A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol Ther 2009; 17(1): 95-103.
[http://dx.doi.org/10.1038/mt.2008.215] [PMID: 18957965]
[29]
Zhou J, Li H, Li S, Zaia J, Rossi JJ. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther 2008; 16(8): 1481-9.
[http://dx.doi.org/10.1038/mt.2008.92] [PMID: 18461053]
[30]
Guo YE, Steitz JA. 3′-Biotin-tagged microRNA-27 does not associate with Argonaute proteins in cells. RNA 2014; 20(7): 985-8.
[http://dx.doi.org/10.1261/rna.045054.114] [PMID: 24821854]
[31]
Shingara J, Keiger K, Shelton J, et al. An optimized isolation and labeling platform for accurate microRNA expression profiling. RNA 2005; 11(9): 1461-70.
[http://dx.doi.org/10.1261/rna.2610405] [PMID: 16043497]
[32]
Shim H, Chun YS, Lewis BC, Dang CV. A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc Natl Acad Sci USA 1998; 95(4): 1511-6.
[http://dx.doi.org/10.1073/pnas.95.4.1511] [PMID: 9465046]
[33]
Yonezawa S, Koide H, Asai T. Recent advances in siRNA delivery mediated by lipid-based nanoparticles. Adv Drug Deliv Rev 2020; 154-155: 64-78.
[http://dx.doi.org/10.1016/j.addr.2020.07.022] [PMID: 32768564]
[34]
Scheideler M, Vidakovic I, Prassl R. Lipid nanocarriers for microRNA delivery. Chem Phys Lipids 2020; 226104837.
[http://dx.doi.org/10.1016/j.chemphyslip.2019.104837] [PMID: 31689410]
[35]
Mainini F, Eccles MR. Lipid and polymer-based nanoparticle siRNA delivery systems for cancer therapy. Molecules 2020; 25(11): 2692.
[http://dx.doi.org/10.3390/molecules25112692] [PMID: 32532030]
[36]
Kapadia CH, Luo B, Dang MN, Irvin-Choy N, Valcourt DM, Day ES. Polymer nanocarriers for MicroRNA delivery. J Appl Polym Sci 2020; 137(25): 48651.
[http://dx.doi.org/10.1002/app.48651] [PMID: 33384460]
[37]
Mbatha LS, Maiyo FC, Singh M. Dendrimer functionalized folate-targeted gold nanoparticles for luciferase gene silencing in vitro: A proof of principle study. Acta Pharm 2019; 69(1): 49-61.
[http://dx.doi.org/10.2478/acph-2019-0008] [PMID: 31259716]
[38]
Maiyo F, Singh M. Polymerized selenium nanoparticles for folate-receptor-targeted delivery of Anti-Luc-siRNA: Potential for gene silencing. Biomedicines 2020; 8(4): 76.
[http://dx.doi.org/10.3390/biomedicines8040076] [PMID: 32260507]
[39]
Pędziwiatr-Werbicka E, Gorzkiewicz M, Horodecka K, et al. Silver nanoparticles surface-modified with carbosilane dendrons as carriers of anticancer siRNA. Int J Mol Sci 2020; 21(13): 4647.
[http://dx.doi.org/10.3390/ijms21134647] [PMID: 32629868]
[40]
Peng J, Wang R, Sun W, et al. Delivery of miR-320a-3p by gold nanoparticles combined with photothermal therapy for directly targeting Sp1 in lung cancer. Biomater Sci 2021; 9(19): 6528-41.
[http://dx.doi.org/10.1039/D1BM01124C] [PMID: 34582541]
[41]
Maiti D, Tong X, Mou X, Yang K. Carbon-based nanomaterials for biomedical applications: A recent study. Front Pharmacol 2019; 9: 1401.
[http://dx.doi.org/10.3389/fphar.2018.01401] [PMID: 30914959]
[42]
Patel KD, Singh RK, Kim HW. Carbon-based nanomaterials as an emerging platform for theranostics. Mater Horiz 2019; 6(3): 434-69.
[http://dx.doi.org/10.1039/C8MH00966J]
[43]
Sajjadi M, Nasrollahzadeh M, Jaleh B, Soufi GJ, Iravani S. Carbon-based nanomaterials for targeted cancer nanotherapy: Recent trends and future prospects. J Drug Target 2021; 29(7): 716-41.
[http://dx.doi.org/10.1080/1061186X.2021.1886301] [PMID: 33566719]
[44]
Simon J, Flahaut E, Golzio M. Overview of carbon nanotubes for biomedical applications. Materials 2019; 12(4): 624.
[http://dx.doi.org/10.3390/ma12040624] [PMID: 30791507]
[45]
Partha R, Conyers JL. Biomedical applications of functionalized fullerene-based nanomaterials. Int J Nanomedicine 2009; 4: 261-75.
[PMID: 20011243]
[46]
Sivasankarapillai VS, Kirthi AV, Akksadha M, Indu S, Dharshini UD, Pushpamalar J, et al. Recent advancements in the applications of carbon nanodots: Exploring the rising star of nanotechnology. Nanoscale Adv 2020; 2(5): 1760-73.
[http://dx.doi.org/10.1039/C9NA00794F]
[47]
Ostadhossein F, Pan D. Functional carbon nanodots for multiscale imaging and therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2017; 9(3): e1436.
[http://dx.doi.org/10.1002/wnan.1436] [PMID: 27791335]
[48]
Moreno-Lanceta A, Medrano-Bosch M, Melgar-Lesmes P. Single-walled carbon nanohorns as promising nanotube-derived delivery systems to treat cancer. Pharmaceutics 2020; 12(9): 850.
[http://dx.doi.org/10.3390/pharmaceutics12090850] [PMID: 32906852]
[49]
Solarska-Ściuk K, Kleszczyńska H. Possibilities of nanodiamonds application–biological and medical aspects. Acta Pol Pharm 2019; 76(5): 779-96.
[http://dx.doi.org/10.32383/appdr/109501]
[50]
Erickson K, Erni R, Lee Z, Alem N, Gannett W, Zettl A. Determination of the local chemical structure of graphene oxide and reduced graphene oxide. Adv Mater 2010; 22(40): 4467-72.
[http://dx.doi.org/10.1002/adma.201000732] [PMID: 20717985]
[51]
Novoselov KS, Geim AK, Morozov SV, et al. Electric field effect in atomically thin carbon films. Science 2004; 306(5696): 666-9.
[http://dx.doi.org/10.1126/science.1102896] [PMID: 15499015]
[52]
Shadjou N, Hasanzadeh M. Graphene and its nanostructure derivatives for use in bone tissue engineering: Recent advances. J Biomed Mater Res A 2016; 104(5): 1250-75.
[http://dx.doi.org/10.1002/jbm.a.35645] [PMID: 26748447]
[53]
Ou L, Song B, Liang H, et al. Toxicity of graphene-family nanoparticles: A general review of the origins and mechanisms. Part Fibre Toxicol 2016; 13(1): 57.
[http://dx.doi.org/10.1186/s12989-016-0168-y] [PMID: 27799056]
[54]
Chau NDQ, Reina G, Raya J, et al. Elucidation of siRNA complexation efficiency by graphene oxide and reduced graphene oxide. Carbon 2017; 122: 643-52.
[http://dx.doi.org/10.1016/j.carbon.2017.07.016]
[55]
de Lázaro I, Vranic S, Marson D, et al. Graphene oxide as a 2D platform for complexation and intracellular delivery of siRNA. Nanoscale 2019; 11(29): 13863-77.
[http://dx.doi.org/10.1039/C9NR02301A] [PMID: 31298676]
[56]
Reina G, Chau NDQ, Nishina Y, Bianco A. Graphene oxide size and oxidation degree govern its supramolecular interactions with siRNA. Nanoscale 2018; 10(13): 5965-74.
[http://dx.doi.org/10.1039/C8NR00333E] [PMID: 29542775]
[57]
Yang X, Niu G, Cao X, et al. The preparation of functionalized graphene oxide for targeted intracellular delivery of siRNA. J Mater Chem 2012; 22(14): 6649-54.
[http://dx.doi.org/10.1039/c2jm14718a]
[58]
Yadav N, Kumar N, Prasad P, Shirbhate S, Sehrawat S, Lochab B. Stable dispersions of covalently tethered polymer improved graphene oxide nanoconjugates as an effective vector for siRNA delivery. ACS Appl Mater Interfaces 2018; 10(17): 14577-93.
[http://dx.doi.org/10.1021/acsami.8b03477] [PMID: 29634909]
[59]
Wang Y, Sun G, Gong Y, Zhang Y, Liang X, Yang L. Functionalized folate-modified graphene oxide/PEI siRNA nanocomplexes for targeted ovarian cancer gene therapy. Nanoscale Res Lett 2020; 15(1): 57.
[http://dx.doi.org/10.1186/s11671-020-3281-7] [PMID: 32140846]
[60]
Yin F, Hu K, Chen Y, et al. SiRNA delivery with PEGylated graphene oxide nanosheets for combined photothermal and genetherapy for pancreatic cancer. Theranostics oxide nanosheets for combined photothermal and genetherapy for pancreatic cancer. Theranostics 2017; 7(5): 1133-48.
[http://dx.doi.org/10.7150/thno.17841] [PMID: 28435453]
[61]
Singh V, Sagar P, Kaul S, Sandhir R, Singhal NK. Liver phosphoenolpyruvate carboxykinase-1 downregulation via siRNA-Functionalized graphene oxide nanosheets restores glucose homeostasis in a type 2 diabetes mellitus in vivo model. Bioconjug Chem 2021; 32(2): 259-78.
[http://dx.doi.org/10.1021/acs.bioconjchem.0c00645] [PMID: 33347265]
[62]
Qu Y, Sun F, He F, et al. Glycyrrhetinic acid-modified graphene oxide mediated siRNA delivery for enhanced liver-cancer targeting therapy. Eur J Pharm Sci 2019; 139: 105036.
[http://dx.doi.org/10.1016/j.ejps.2019.105036] [PMID: 31446078]
[63]
Wang X, Sun Q, Cui C, Li J, Wang Y. Anti-HER2 functionalized graphene oxide as survivin-siRNA delivery carrier inhibits breast carcinoma growth in vitro and in vivo. Drug Des Devel Ther 2018; 12: 2841-55.
[http://dx.doi.org/10.2147/DDDT.S169430] [PMID: 30233146]
[64]
Ren L, Zhang Y, Cui C, Bi Y, Ge X. Functionalized graphene oxide for anti-VEGF siRNA delivery: Preparation, characterization and evaluation in vitro and in vivo. RSC Advances 2017; 7(33): 20553-66.
[http://dx.doi.org/10.1039/C7RA00810D]
[65]
Huang YP, Hung CM, Hsu YC, et al. Suppression of breast cancer cell migration by small interfering RNA delivered by polyethylenimine-functionalized graphene oxide. Nanoscale Res Lett 2016; 11(1): 247.
[http://dx.doi.org/10.1186/s11671-016-1463-0] [PMID: 27173676]
[66]
Li J, Ge X, Cui C, et al. Preparation and characterization of functionalized graphene oxide carrier for siRNA delivery. Int J Mol Sci 2018; 19(10): 3202.
[http://dx.doi.org/10.3390/ijms19103202] [PMID: 30336549]
[67]
Zhang L, Zhou Q, Song W, Wu K, Zhang Y, Zhao Y. Dual-functionalized graphene oxide based siRNA delivery system for implant surface biomodification with enhanced osteogenesis. ACS Appl Mater Interfaces 2017; 9(40): 34722-35.
[http://dx.doi.org/10.1021/acsami.7b12079] [PMID: 28925678]
[68]
Sun Y, Zhou J, Cheng Q, et al. Fabrication of mPEGylated graphene oxide/poly (2‐dimethyl aminoethyl methacrylate) nanohybrids and their primary application for small interfering RNA delivery. J Appl Polym Sci 2016; 133(6): 43303.
[http://dx.doi.org/10.1002/app.43303]
[69]
Joo J, Kwon EJ, Kang J, et al. Porous silicon-graphene oxide core-shell nanoparticles for targeted delivery of siRNA to the injured brain. Nanoscale Horiz 2016; 1(5): 407-14.
[http://dx.doi.org/10.1039/C6NH00082G] [PMID: 29732165]
[70]
Saravanabhavan SS, Rethinasabapathy M, Zsolt S, et al. Graphene oxide functionalized with chitosan based nanoparticles as a carrier of siRNA in regulating Bcl-2 expression on Saos-2 & MG-63 cancer cells and its inflammatory response on bone marrow derived cells from mice. Mater Sci Eng C 2019; 99: 1459-68.
[http://dx.doi.org/10.1016/j.msec.2019.02.047] [PMID: 30889680]
[71]
Cao X, Feng F, Wang Y, Yang X, Duan H, Chen Y. Folic acid-conjugated graphene oxide as a transporter of chemotherapeutic drug and siRNA for reversal of cancer drug resistance. J Nanopart Res 2013; 15(10): 1-12.
[http://dx.doi.org/10.1007/s11051-013-1965-y]
[72]
Zhang L, Lu Z, Zhao Q, Huang J, Shen H, Zhang Z. Enhanced chemotherapy efficacy by sequential delivery of siRNA and anticancer drugs using PEI-grafted graphene oxide. Small 2011; 7(4): 460-4.
[http://dx.doi.org/10.1002/smll.201001522] [PMID: 21360803]
[73]
Sun Q, Wang X, Cui C, Li J, Wang Y. Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo. Int J Nanomedicine 2018; 13: 3713-28.
[http://dx.doi.org/10.2147/IJN.S162939] [PMID: 29983564]
[74]
Izadi S, Moslehi A, Kheiry H, et al. Codelivery of HIF-1α siRNA and dinaciclib by carboxylated graphene oxide-trimethyl chitosan-hyaluronate nanoparticles significantly suppresses cancer cell progression. Pharm Res 2020; 37(10): 196.
[http://dx.doi.org/10.1007/s11095-020-02892-y] [PMID: 32944844]
[75]
Yin D, Li Y, Lin H, et al. Functional graphene oxide as a plasmid-based Stat3 siRNA carrier inhibits mouse malignant melanoma growth in vivo. Nanotechnology 2013; 24(10): 105102.
[http://dx.doi.org/10.1088/0957-4484/24/10/105102] [PMID: 23425941]
[76]
Yin D, Li Y, Guo B, et al. Plasmid-based Stat3 siRNA delivered by functional graphene oxide suppresses mouse malignant melanoma cell growth. Oncol Res 2016; 23(5): 229-36.
[http://dx.doi.org/10.3727/096504016X14550280421449] [PMID: 27098146]
[77]
He Y, Zhang L, Chen Z, et al. Enhanced chemotherapy efficacy by co-delivery of shABCG2 and doxorubicin with a pH-responsive charge-reversible layered graphene oxide nanocomplex. J Mater Chem B Mater Biol Med 2015; 3(31): 6462-72.
[http://dx.doi.org/10.1039/C5TB00923E] [PMID: 32262554]
[78]
Gu Y, Guo Y, Wang C, et al. A polyamidoamne dendrimer functionalized graphene oxide for DOX and MMP-9 shRNA plasmid co-delivery. Mater Sci Eng C 2017; 70(Pt 1): 572-85.
[http://dx.doi.org/10.1016/j.msec.2016.09.035] [PMID: 27770930]
[79]
Liu T, Li J, Wu X, et al. Transferrin-targeting redox hyperbranched poly(amido amine)-functionalized graphene oxide for sensitized chemotherapy combined with gene therapy to nasopharyngeal carcinoma. Drug Deliv 2019; 26(1): 744-55.
[http://dx.doi.org/10.1080/10717544.2019.1642421] [PMID: 31340676]
[80]
Lu YJ, Lan YH, Chuang CC, et al. Injectable thermo-sensitive chitosan hydrogel containing CPT-11-loaded EGFR-targeted graphene oxide and SLP2 shRNA for localized drug/gene delivery in glioblastoma therapy. Int J Mol Sci 2020; 21(19): 7111.
[http://dx.doi.org/10.3390/ijms21197111] [PMID: 32993166]
[81]
Ou L, Sun T, Liu M, et al. Efficient miRNA inhibitor delivery with graphene oxide-polyethylenimine to inhibit oral squamous cell carcinoma. Int J Nanomedicine 2020; 15: 1569-83.
[http://dx.doi.org/10.2147/IJN.S220057] [PMID: 32210552]
[82]
Ou L, Lin H, Song Y, et al. Efficient miRNA inhibitor with GO-PEI nanosheets for osteosarcoma suppression by targeting PTEN. Int J Nanomedicine 2020; 15: 5131-46.
[http://dx.doi.org/10.2147/IJN.S257084] [PMID: 32764941]
[83]
Assali A, Akhavan O, Mottaghitalab F, et al. Cationic graphene oxide nanoplatform mediates miR-101 delivery to promote apoptosis by regulating autophagy and stress. Int J Nanomedicine 2018; 13: 5865-86.
[http://dx.doi.org/10.2147/IJN.S162647] [PMID: 30319254]
[84]
Assali A, Akhavan O, Adeli M, et al. Multifunctional core-shell nanoplatforms (gold@graphene oxide) with mediated NIR thermal therapy to promote miRNA delivery. Nanomedicine 2018; 14(6): 1891-903.
[http://dx.doi.org/10.1016/j.nano.2018.05.016] [PMID: 29885900]
[85]
Liu C, Xie H, Yu J, et al. A targeted therapy for melanoma by graphene oxide composite with microRNA carrier. Drug Des Devel Ther 2018; 12: 3095-106.
[http://dx.doi.org/10.2147/DDDT.S160088] [PMID: 30275686]
[86]
Yang H, Shi G, Ge C, et al. Functionalized graphene oxide as a nanocarrier for multiple suppressive miRNAs to inhibit human intrahepatic cholangiocarcinoma. Nano Select 2021; 2(7): 1372-84.
[http://dx.doi.org/10.1002/nano.202000130]
[87]
Zhi F, Dong H, Jia X, et al. Functionalized graphene oxide mediated adriamycin delivery and miR-21 gene silencing to overcome tumor multidrug resistance in vitro. PLoS One 2013; 8(3): e60034.
[http://dx.doi.org/10.1371/journal.pone.0060034] [PMID: 23527297]
[88]
Yang HW, Huang CY, Lin CW, et al. Gadolinium-functionalized nanographene oxide for combined drug and microRNA delivery and magnetic resonance imaging. Biomaterials 2014; 35(24): 6534-42.
[http://dx.doi.org/10.1016/j.biomaterials.2014.04.057] [PMID: 24811259]
[89]
Yan J, Zhang Y, Zheng L, et al. Let-7i miRNA and platinum loaded nano-graphene oxide platform for detection/reversion of drug resistance and synergetic chemical-photothermal inhibition of cancer cell. Chin Chem Lett 2022; 33: 767-72.
[http://dx.doi.org/10.1016/j.cclet.2021.08.018]
[90]
Iijima S. Carbon nanotubes: past, present, and future. Physica B 2002; 323(1-4): 1-5.
[http://dx.doi.org/10.1016/S0921-4526(02)00869-4]
[91]
Heersche HB, Jarillo-Herrero P, Oostinga JB, Vandersypen LM, Morpurgo AF. Bipolar supercurrent in graphene. Nature 2007; 446(7131): 56-9.
[http://dx.doi.org/10.1038/nature05555] [PMID: 17330038]
[92]
Madani SY, Naderi N, Dissanayake O, Tan A, Seifalian AM. A new era of cancer treatment: Carbon nanotubes as drug delivery tools. Int J Nanomedicine 2011; 6: 2963-79.
[PMID: 22162655]
[93]
Eivazzadeh-Keihan R, Maleki A, de la Guardia M, et al. Carbon based nanomaterials for tissue engineering of bone: Building new bone on small black scaffolds: A review. J Adv Res 2019; 18: 185-201.
[http://dx.doi.org/10.1016/j.jare.2019.03.011] [PMID: 31032119]
[94]
Yang ST, Guo W, Lin Y, et al. Biodistribution of pristine single-walled carbon nanotubes in vivo. J Phys Chem C 2007; 111(48): 17761-4.
[http://dx.doi.org/10.1021/jp070712c]
[95]
Ding Y, Tian R, Yang Z, Chen J, Lu N. Binding of human IgG to single-walled carbon nanotubes accelerated myeloperoxidase-mediated degradation in activated neutrophils. Biophys Chem 2016; 218: 36-41.
[http://dx.doi.org/10.1016/j.bpc.2016.09.001] [PMID: 27614147]
[96]
Li T, Zhang CZ, Fan X, Li Y, Song M. Degradation of oxidized multi-walled carbon nanotubes in water via photo-Fenton method and its degradation mechanism. Chem Eng J 2017; 323: 37-46.
[http://dx.doi.org/10.1016/j.cej.2017.04.081]
[97]
Varkouhi AK, Foillard S, Lammers T, et al. SiRNA delivery with functionalized carbon nanotubes. Int J Pharm 2011; 416(2): 419-25.
[http://dx.doi.org/10.1016/j.ijpharm.2011.02.009] [PMID: 21320582]
[98]
Becker ML, Fagan JA, Gallant ND, et al. Length-dependent uptake of DNA-wrapped single-walled carbon nanotubes. Adv Mater 2007; 19(7): 939-45.
[http://dx.doi.org/10.1002/adma.200602667]
[99]
Kam NWS, Liu Z, Dai H. Carbon nanotubes as intracellular transporters for proteins and DNA: An investigation of the uptake mechanism and pathway. Angew Chem Int Ed 2006; 45(4): 577-81.
[http://dx.doi.org/10.1002/anie.200503389] [PMID: 16345107]
[100]
Huang YP, Lin IJ, Chen CC, Hsu YC, Chang CC, Lee M-J. Delivery of small interfering RNAs in human cervical cancer cells by polyethylenimine-functionalized carbon nanotubes. Nanoscale Res Lett 2013; 8(1): 267.
[http://dx.doi.org/10.1186/1556-276X-8-267] [PMID: 23742156]
[101]
Mogurampelly S, Maiti PK. Translocation and encapsulation of siRNA inside carbon nanotubes. J Chem Phys 2013; 138(3): 034901.
[http://dx.doi.org/10.1063/1.4773302] [PMID: 23343299]
[102]
Kirkpatrick DL, Weiss M, Naumov A, Bartholomeusz G, Weisman RB, Gliko O. Carbon nanotubes: Solution for the therapeutic delivery of siRNA? Materials 2012; 5(2): 278-301.
[http://dx.doi.org/10.3390/ma5020278] [PMID: 28817045]
[103]
Anderson T, Hu R, Yang C, Yoon HS, Yong K-T. Pancreatic cancer gene therapy using an siRNA-functionalized single walled carbon nanotubes (SWNTs) nanoplex. Biomater Sci 2014; 2(9): 1244-53.
[http://dx.doi.org/10.1039/C4BM00019F] [PMID: 32481895]
[104]
Ladeira MS, Andrade VA, Gomes ER, et al. Highly efficient siRNA delivery system into human and murine cells using single-wall carbon nanotubes. Nanotechnology 2010; 21(38): 385101.
[http://dx.doi.org/10.1088/0957-4484/21/38/385101] [PMID: 20798464]
[105]
Neagoe IB, Braicu C, Matea C, et al. Efficient siRNA delivery system using carboxilated single-wall carbon nanotubes in cancer treatment. J Biomed Nanotechnol 2012; 8(4): 567-74.
[http://dx.doi.org/10.1166/jbn.2012.1411] [PMID: 22852466]
[106]
Spinato C, Giust D, Vacchi IA, Ménard-Moyon C, Kostarelos K, Bianco A. Different chemical strategies to aminate oxidised multi-walled carbon nanotubes for siRNA complexation and delivery. J Mater Chem B Mater Biol Med 2016; 4(3): 431-41.
[http://dx.doi.org/10.1039/C5TB02088C] [PMID: 32263207]
[107]
Battigelli A, Wang JTW, Russier J, et al. Ammonium and guanidinium dendron-carbon nanotubes by amidation and click chemistry and their use for siRNA delivery. Small 2013; 9(21): 3610-9.
[http://dx.doi.org/10.1002/smll.201300264] [PMID: 23650276]
[108]
Li H, Hao Y, Wang N, et al. DOTAP functionalizing single-walled carbon nanotubes as non-viral vectors for efficient intracellular siRNA delivery. Drug Deliv 2016; 23(3): 840-8.
[http://dx.doi.org/10.3109/10717544.2014.919542] [PMID: 24892622]
[109]
Foillard S, Zuber G, Doris E. Polyethylenimine-carbon nanotube nanohybrids for siRNA-mediated gene silencing at cellular level. Nanoscale 2011; 3(4): 1461-4.
[http://dx.doi.org/10.1039/c0nr01005g] [PMID: 21301705]
[110]
Siu KS, Zheng X, Liu Y, et al. Single-walled carbon nanotubes noncovalently functionalized with lipid modified polyethylenimine for siRNA delivery in vitro and in vivo. Bioconjug Chem 2014; 25(10): 1744-51.
[http://dx.doi.org/10.1021/bc500280q] [PMID: 25216445]
[111]
Siu KS, Chen D, Zheng X, et al. Non-covalently functionalized single-walled carbon nanotube for topical siRNA delivery into melanoma. Biomaterials 2014; 35(10): 3435-42.
[http://dx.doi.org/10.1016/j.biomaterials.2013.12.079] [PMID: 24424208]
[112]
Chen H, Ma X, Li Z, et al. Functionalization of single-walled carbon nanotubes enables efficient intracellular delivery of siRNA targeting MDM2 to inhibit breast cancer cells growth. Biomed Pharmacother 2012; 66(5): 334-8.
[http://dx.doi.org/10.1016/j.biopha.2011.12.005] [PMID: 22397761]
[113]
Wang L, Shi J, Zhang H, et al. Synergistic anticancer effect of RNAi and photothermal therapy mediated by functionalized single-walled carbon nanotubes. Biomaterials 2013; 34(1): 262-74.
[http://dx.doi.org/10.1016/j.biomaterials.2012.09.037] [PMID: 23046752]
[114]
Wang L, Shi J, Zhang H, Li H, Gao Y, Wang Z, et al. Dendrimer modified SWCNTs for high efficient delivery and intracellular imaging of survivin siRNA. Nano Biomed Eng 2013; 5(3): 131-6.
[http://dx.doi.org/10.5101/nbe.v5i3.p131-136]
[115]
Mohammadi M, Salmasi Z, Hashemi M, Mosaffa F, Abnous K, Ramezani M. Single-walled carbon nanotubes functionalized with aptamer and piperazine-polyethylenimine derivative for targeted siRNA delivery into breast cancer cells. Int J Pharm 2015; 485(1-2): 50-60.
[http://dx.doi.org/10.1016/j.ijpharm.2015.02.031] [PMID: 25712164]
[116]
Taghavi S. HashemNia A, Mosaffa F, Askarian S, Abnous K, Ramezani M. Preparation and evaluation of polyethylenimine-functionalized carbon nanotubes tagged with 5TR1 aptamer for targeted delivery of Bcl-xL shRNA into breast cancer cells. Colloids Surf B Biointerfaces 2016; 140: 28-39.
[http://dx.doi.org/10.1016/j.colsurfb.2015.12.021] [PMID: 26731195]
[117]
Taghavi S, Nia AH, Abnous K, Ramezani M. Polyethylenimine-functionalized carbon nanotubes tagged with AS1411 aptamer for combination gene and drug delivery into human gastric cancer cells. Int J Pharm 2017; 516(1-2): 301-12.
[http://dx.doi.org/10.1016/j.ijpharm.2016.11.027] [PMID: 27840158]
[118]
Ren X, Lin J, Wang X, et al. Photoactivatable RNAi for cancer gene therapy triggered by near-infrared-irradiated single-walled carbon nanotubes. Int J Nanomedicine 2017; 12: 7885-96.
[http://dx.doi.org/10.2147/IJN.S141882] [PMID: 29138556]
[119]
Guo C, Al-Jamal WT, Toma FM, et al. Design of cationic multiwalled carbon nanotubes as efficient siRNA vectors for lung cancer xenograft eradication. Bioconjug Chem 2015; 26(7): 1370-9.
[http://dx.doi.org/10.1021/acs.bioconjchem.5b00249] [PMID: 26036843]
[120]
Pereira S, Lee J, Rubio N, et al. Cationic liposome-multi-walled carbon nanotubes hybrids for dual siPLK1 and doxorubicin delivery in vitro. Pharm Res 2015; 32(10): 3293-308.
[http://dx.doi.org/10.1007/s11095-015-1707-1] [PMID: 26085038]
[121]
Al-Jamal KT, Gherardini L, Bardi G, et al. Functional motor recovery from brain ischemic insult by carbon nanotube-mediated siRNA silencing. Proc Natl Acad Sci USA 2011; 108(27): 10952-7.
[http://dx.doi.org/10.1073/pnas.1100930108] [PMID: 21690348]
[122]
Hasan MT, Campbell E, Sizova O, et al. Multi-drug/gene NASH therapy delivery and selective hyperspectral NIR imaging using chirality-sorted single-walled carbon nanotubes. Cancers 2019; 11(8): 1175.
[http://dx.doi.org/10.3390/cancers11081175] [PMID: 31416250]
[123]
Masotti A, Miller MR, Celluzzi A, et al. Regulation of angiogenesis through the efficient delivery of microRNAs into endothelial cells using polyamine-coated carbon nanotubes. Nanomedicine 2016; 12(6): 1511-22.
[http://dx.doi.org/10.1016/j.nano.2016.02.017] [PMID: 27013131]
[124]
Celluzzi A, Paolini A, D’Oria V, et al. Biophysical and biological contributions of polyamine-coated carbon nanotubes and bidimensional buckypapers in the delivery of miRNAs to human cells. Int J Nanomedicine 2017; 13: 1-18.
[http://dx.doi.org/10.2147/IJN.S144155] [PMID: 29296082]
[125]
Kroto HW, Heath JR, O’Brien SC, Curl RF, Smalley RE. C60: buckminsterfullerene. Nature 1985; 318(6042): 162-3.
[http://dx.doi.org/10.1038/318162a0]
[126]
Arbogast JW, Darmanyan AP, Foote CS, et al. Photophysical properties of sixty atom carbon molecule (C60). J Phys Chem 1991; 95(1): 11-2.
[http://dx.doi.org/10.1021/j100154a006]
[127]
Xie Q, Perez-Cordero E, Echegoyen L. Electrochemical detection of C606-and C706-: Enhanced stability of fullerides in solution. J Am Chem Soc 1992; 114(10): 3978-80.
[http://dx.doi.org/10.1021/ja00036a056]
[128]
Singh S. Nanomaterials as non-viral siRNA delivery agents for cancer therapy. Bioimpacts 2013; 3(2): 53-65.
[PMID: 23878788]
[129]
Nakamura E, Isobe H. Functionalized fullerenes in water. The first 10 years of their chemistry, biology, and nanoscience. Acc Chem Res 2003; 36(11): 807-15.
[http://dx.doi.org/10.1021/ar030027y] [PMID: 14622027]
[130]
Minami K, Okamoto K, Doi K, Harano K, Noiri E, Nakamura E. siRNA delivery targeting to the lung via agglutination-induced accumulation and clearance of cationic tetraamino fullerene. Sci Rep 2014; 4(1): 4916.
[http://dx.doi.org/10.1038/srep04916] [PMID: 24814863]
[131]
Minami K, Okamoto K, Harano K, Noiri E, Nakamura E. Hierarchical assembly of siRNA with tetraamino fullerene in physiological conditions for efficient internalization into cells and knockdown. ACS Appl Mater Interfaces 2018; 10(23): 19347-54.
[http://dx.doi.org/10.1021/acsami.8b01869] [PMID: 29742343]
[132]
Wang J, Xie L, Wang T, et al. Visible light-switched cytosol release of siRNA by amphiphilic fullerene derivative to enhance RNAi efficacy in vitro and in vivo. Acta Biomater 2017; 59: 158-69.
[http://dx.doi.org/10.1016/j.actbio.2017.05.031] [PMID: 28511875]
[133]
Voicu G, Rebleanu D, Constantinescu CA, et al. Nano-polyplexes mediated transfection of Runx2-shRNA mitigates the osteodifferentiation of human valvular interstitial cells. Pharmaceutics 2020; 12(6): 507.
[http://dx.doi.org/10.3390/pharmaceutics12060507] [PMID: 32498305]
[134]
Cohen EN, Kondiah PPD, Choonara YE, du Toit LC, Pillay V. Carbon dots as nanotherapeutics for biomedical application. Curr Pharm Des 2020; 26(19): 2207-21.
[http://dx.doi.org/10.2174/1381612826666200402102308] [PMID: 32238132]
[135]
Wang Q, Zhang C, Shen G, Liu H, Fu H, Cui D. Fluorescent carbon dots as an efficient siRNA nanocarrier for its interference therapy in gastric cancer cells. J Nanobiotechnology 2014; 12(1): 58.
[http://dx.doi.org/10.1186/s12951-014-0058-0] [PMID: 25547381]
[136]
Wang L, Wang X, Bhirde A, et al. Carbon-dot-based two-photon visible nanocarriers for safe and highly efficient delivery of siRNA and DNA. Adv Healthc Mater 2014; 3(8): 1203-9.
[http://dx.doi.org/10.1002/adhm.201300611] [PMID: 24692418]
[137]
Wang HJ, He X, Luo TY, Zhang J, Liu YH, Yu XQ. Amphiphilic carbon dots as versatile vectors for nucleic acid and drug delivery. Nanoscale 2017; 9(18): 5935-47.
[http://dx.doi.org/10.1039/C7NR01029J] [PMID: 28440819]
[138]
Li R, Wei F, Wu X, et al. PEI modified orange emissive carbon dots with excitation-independent fluorescence emission for cellular imaging and siRNA delivery. Carbon 2021; 177: 403-11.
[http://dx.doi.org/10.1016/j.carbon.2021.02.069]
[139]
Wu Y-F, Wu H-C, Kuan C-H, et al. Multi-functionalized carbon dots as theranostic nanoagent for gene delivery in lung cancer therapy. Sci Rep 2016; 6(1): 21170.
[http://dx.doi.org/10.1038/srep21170] [PMID: 26880047]
[140]
Shu M, Gao F, Yu C, et al. Dual-targeted therapy in HER2-positive breast cancer cells with the combination of carbon dots/HER3 siRNA and trastuzumab. Nanotechnology 2020; 31(33): 335102.
[http://dx.doi.org/10.1088/1361-6528/ab8a8a] [PMID: 32303014]
[141]
Wang J, Liu S, Chang Y, Fang L, Han K, Li M. High efficient delivery of siRNA into tumor cells by positively charged carbon dots. J Macromol Sci Part A Pure Appl Chem 2018; 55(11-12): 770-4.
[http://dx.doi.org/10.1080/10601325.2018.1526043]
[142]
Ju E, Li T, Liu Z, et al. Specific inhibition of viral microRNAs by carbon dots-mediated delivery of locked nucleic acids for therapy of virus-induced cancer. ACS Nano 2020; 14(1): 476-87.
[http://dx.doi.org/10.1021/acsnano.9b06333] [PMID: 31895530]
[143]
Bu W, Xu X, Wang Z, et al. Ascorbic Acid-PEI carbon dots with osteogenic effects as miR-2861 carriers to effectively enhance bone regeneration. ACS Appl Mater Interfaces 2020; 12(45): 50287-302.
[http://dx.doi.org/10.1021/acsami.0c15425] [PMID: 33121247]
[144]
Karfa P, De S, Majhi KC, Madhuri R, Sharma PK. 207 - Functionalization of carbon nanostructures In: Andrews DL, Lipson RH, Nann T, Eds Comprehensive Nanoscience and Nanotechnology 2nd ed Oxford: Academic Press 2019; pp. 123-44.
[http://dx.doi.org/10.1016/B978-0-12-803581-8.11225-1]
[145]
Bianco A, Kostarelos K, Prato M. Opportunities and challenges of carbon-based nanomaterials for cancer therapy. Expert Opin Drug Deliv 2008; 5(3): 331-42.
[http://dx.doi.org/10.1517/17425247.5.3.331] [PMID: 18318654]
[146]
Guerra J, Herrero MA, Carrion B, et al. Carbon nanohorns functionalized with polyamidoamine dendrimers as efficient biocarrier materials for gene therapy. Carbon 2012; 50(8): 2832-44.
[http://dx.doi.org/10.1016/j.carbon.2012.02.050]
[147]
Pérez-Martínez FC, Carrión B, Lucío MI, et al. Enhanced docetaxel-mediated cytotoxicity in human prostate cancer cells through knockdown of cofilin-1 by carbon nanohorn delivered siRNA. Biomaterials 2012; 33(32): 8152-9.
[http://dx.doi.org/10.1016/j.biomaterials.2012.07.038] [PMID: 22858003]
[148]
Taherpour AA, Mousavi F. Carbon nanomaterials for electroanalysis in pharmaceutical applications.In: Fullerens, Graphenes and Nanotubes. (1st ed.). Amsterdam: Elsevier 2018; pp. 169-225.
[http://dx.doi.org/10.1016/B978-0-12-813691-1.00006-3]
[149]
Medina-Cruz D, Saleh B, Vernet-Crua A, Ajo A, Roy AK, Webster TJ. Drug-delivery nanocarriers for skin wound-healing applications Wound healing, tissue repair, and regeneration in diabetes In: Bagchi D, Das A, Roy S, Eds Wound Healing, Tissue Repair, and Regeneration in Diabetes 1st ed Amsterdam: Elsevier 2020; pp. 439-88.
[http://dx.doi.org/10.1016/B978-0-12-816413-6.00022-8]
[150]
Chen M, Zhang X-Q, Man HB, Lam R, Chow EK, Ho D. Nanodiamond vectors functionalized with polyethylenimine for siRNA delivery. J Phys Chem Lett 2010; 1(21): 3167-71.
[http://dx.doi.org/10.1021/jz1013278]
[151]
Alhaddad A, Durieu C, Dantelle G, et al. Influence of the internalization pathway on the efficacy of siRNA delivery by cationic fluorescent nanodiamonds in the Ewing sarcoma cell model. PLoS One 2012; 7(12): e52207.
[http://dx.doi.org/10.1371/journal.pone.0052207] [PMID: 23284935]
[152]
Lim DG, Rajasekaran N, Lee D, et al. Polyamidoamine-decorated nanodiamonds as a hybrid gene delivery vector and siRNA structural characterization at the charged interfaces. ACS Appl Mater Interfaces 2017; 9(37): 31543-56.
[http://dx.doi.org/10.1021/acsami.7b09624] [PMID: 28853284]
[153]
Kaur R, Chitanda JM, Michel D, et al. Lysine-functionalized nanodiamonds: Synthesis, physiochemical characterization, and nucleic acid binding studies. Int J Nanomedicine 2012; 7: 3851-66.
[PMID: 22904623]
[154]
Alwani S, Kaur R, Michel D, et al. Lysine-functionalized nanodiamonds as gene carriers: Development of stable colloidal dispersion for in vitro cellular uptake studies and siRNA delivery application. Int J Nanomedicine 2016; 11: 687-702.
[PMID: 26929623]
[155]
Bi Y, Zhang Y, Cui C, Ren L, Jiang X. Gene-silencing effects of anti-survivin siRNA delivered by RGDV-functionalized nanodiamond carrier in the breast carcinoma cell line MCF-7. Int J Nanomedicine 2016; 11: 5771-87.
[http://dx.doi.org/10.2147/IJN.S117611] [PMID: 27853365]
[156]
Cui C, Wang Y, Zhao W, et al. RGDS covalently surfaced nanodiamond as a tumor targeting carrier of VEGF-siRNA: Synthesis, characterization and bioassay. J Mater Chem B Mater Biol Med 2015; 3(48): 9260-8.
[http://dx.doi.org/10.1039/C5TB01602A] [PMID: 32262925]
[157]
Alhaddad A, Adam MP, Botsoa J, et al. Nanodiamond as a vector for siRNA delivery to Ewing sarcoma cells. Small 2011; 7(21): 3087-95.
[http://dx.doi.org/10.1002/smll.201101193] [PMID: 21913326]
[158]
Bertrand JR, Pioche-Durieu C, Ayala J, et al. Plasma hydrogenated cationic detonation nanodiamonds efficiently deliver to human cells in culture functional siRNA targeting the Ewing sarcoma junction oncogene. Biomaterials 2015; 45: 93-8.
[http://dx.doi.org/10.1016/j.biomaterials.2014.12.007] [PMID: 25662499]
[159]
Claveau S, Nehlig É, Garcia-Argote S, et al. Delivery of siRNA to ewing sarcoma tumor xenografted on Mice, using hydrogenated detonation nanodiamonds: Treatment efficacy and tissue distribution. Nanomaterials 2020; 10(3): 553.
[http://dx.doi.org/10.3390/nano10030553] [PMID: 32204428]
[160]
Claveau S, Kindermann M, Papine A, et al. Harnessing subcellular-resolved organ distribution of cationic copolymer-functionalized fluorescent nanodiamonds for optimal delivery of active siRNA to a xenografted tumor in mice. Nanoscale 2021; 13(20): 9280-92.
[http://dx.doi.org/10.1039/D1NR00146A] [PMID: 33982741]
[161]
Cao M, Deng X, Su S, et al. Protamine sulfate-nanodiamond hybrid nanoparticles as a vector for MiR-203 restoration in esophageal carcinoma cells. Nanoscale 2013; 5(24): 12120-5.
[http://dx.doi.org/10.1039/c3nr04056a] [PMID: 24154605]
[162]
Xia Y, Deng X, Cao M, et al. Nanodiamond-based layer-by-layer nanohybrids mediate targeted delivery of miR-34a for triple negative breast cancer therapy. RSC Advances 2018; 8(25): 13789-97.
[http://dx.doi.org/10.1039/C8RA00907D]
[163]
Liu CY, Lee MC, Lin H-F, et al. Nanodiamond-based microRNA delivery system promotes pluripotent stem cells toward myocardiogenic reprogramming. J Chin Med Assoc 2021; 84(2): 177-82.
[http://dx.doi.org/10.1097/JCMA.0000000000000441] [PMID: 33009207]
[164]
Lukowski S, Neuhoferova E, Kinderman M, et al. Fluorescent nanodiamonds are efficient, easy-to-use cyto-compatible vehicles for monitored delivery of non-coding regulatory RNAs. J Biomed Nanotechnol 2018; 14(5): 946-58.
[http://dx.doi.org/10.1166/jbn.2018.2540] [PMID: 29883564]
[165]
Křivohlavá R, Neuhӧferová E, Jakobsen KQ, Benson V. Knockdown of microRNA-135b in mammary carcinoma by targeted nanodiamonds: Potentials and pitfalls of in vivo applications. Nanomaterials 2019; 9(6): 866.
[http://dx.doi.org/10.3390/nano9060866] [PMID: 31181619]
[166]
Kam NWS, Liu Z, Dai H. Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. J Am Chem Soc 2005; 127(36): 12492-3.
[http://dx.doi.org/10.1021/ja053962k] [PMID: 16144388]
[167]
Debnath SK, Srivastava R. Drug delivery with carbon-based nanomaterials as versatile nanocarriers: Progress and prospects. Front Nanotechnol 2021; 3: 15.
[http://dx.doi.org/10.3389/fnano.2021.644564]
[168]
Kim S, Choi Y, Park G, et al. Highly efficient gene silencing and bioimaging based on fluorescent carbon dots in vitro and in vivo. Nano Res 2017; 10(2): 503-19.
[http://dx.doi.org/10.1007/s12274-016-1309-1]
[169]
Yang M, Zhang M. Biodegradation of carbon nanotubes by macrophages. Front Mater 2019; 6: 225.
[http://dx.doi.org/10.3389/fmats.2019.00225]
[170]
Shipkowski KA, Sanders JM, McDonald JD, Walker NJ, Waidyanatha S. Disposition of fullerene C60 in rats following intratracheal or intravenous administration. Xenobiotica 2019; 49(9): 1078-85.
[http://dx.doi.org/10.1080/00498254.2018.1528646] [PMID: 30257131]
[171]
Jasim DA, Ménard-Moyon C, Bégin D, Bianco A, Kostarelos K. Tissue distribution and urinary excretion of intravenously administered chemically functionalized graphene oxide sheets. Chem Sci 2015; 6(7): 3952-64.
[http://dx.doi.org/10.1039/C5SC00114E] [PMID: 28717461]
[172]
Yuan Y, Wang X, Jia G, et al. Pulmonary toxicity and translocation of nanodiamonds in mice. Diamond Related Materials 2010; 19(4): 291-9.
[http://dx.doi.org/10.1016/j.diamond.2009.11.022]
[173]
Seabra AB, Paula AJ, de Lima R, Alves OL, Durán N. Nanotoxicity of graphene and graphene oxide. Chem Res Toxicol 2014; 27(2): 159-68.
[http://dx.doi.org/10.1021/tx400385x] [PMID: 24422439]
[174]
Alshehri R, Ilyas AM, Hasan A, Arnaout A, Ahmed F, Memic A. Carbon nanotubes in biomedical applications: Factors, mechanisms, and remedies of toxicity: Miniperspective. J Med Chem 2016; 59(18): 8149-67.
[http://dx.doi.org/10.1021/acs.jmedchem.5b01770] [PMID: 27142556]

Rights & Permissions Print Cite
Article Metrics
1
© 2024 Bentham Science Publishers | Privacy Policy